Nothing Special   »   [go: up one dir, main page]

NO20101069L - Anvendelse av visse NMDA-affinitetsantagonister som antidepressiva - Google Patents

Anvendelse av visse NMDA-affinitetsantagonister som antidepressiva

Info

Publication number
NO20101069L
NO20101069L NO20101069A NO20101069A NO20101069L NO 20101069 L NO20101069 L NO 20101069L NO 20101069 A NO20101069 A NO 20101069A NO 20101069 A NO20101069 A NO 20101069A NO 20101069 L NO20101069 L NO 20101069L
Authority
NO
Norway
Prior art keywords
antidepressants
hydrogen
affinity antagonists
certain nmda
fluorophenyl
Prior art date
Application number
NO20101069A
Other languages
English (en)
Inventor
Dennis Mccarthy
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of NO20101069L publication Critical patent/NO20101069L/no
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Anvendelse av visse lavaffinitet-NMDA-antagonister som antidepressive midler. Foretrukne forbindelser inkluderer forbindelser av formel (I) R2 | R5 R1 ? CH2 ??? N | R4 R3 (I) Hvor R1 er pyridyl, fenyl eller 4-fluorfenyl; R2 er fenyl eller 4-fluorfenyl; R3 er hydrogen, C1-6 alkyl eller metoksykarbonyl; R4 er hydrogen eller metyl; og R5 er hydrogen eller COCH2NH2, og farmasøytisk akseptable salter derav.
NO20101069A 1999-03-23 2010-07-27 Anvendelse av visse NMDA-affinitetsantagonister som antidepressiva NO20101069L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9901077A SE9901077D0 (sv) 1999-03-23 1999-03-23 Novel use
PCT/SE2000/000540 WO2000056324A1 (en) 1999-03-23 2000-03-21 The use of certain affinity nmda antagonists as antidepressants

Publications (1)

Publication Number Publication Date
NO20101069L true NO20101069L (no) 2001-09-06

Family

ID=20414989

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20014345A NO330550B1 (no) 1999-03-23 2001-09-06 Anvendelse av NMDA-affinitetsantagonist som antidepressiva
NO20101069A NO20101069L (no) 1999-03-23 2010-07-27 Anvendelse av visse NMDA-affinitetsantagonister som antidepressiva

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20014345A NO330550B1 (no) 1999-03-23 2001-09-06 Anvendelse av NMDA-affinitetsantagonist som antidepressiva

Country Status (17)

Country Link
US (1) US6479553B1 (no)
EP (1) EP1162967A1 (no)
JP (1) JP4705717B2 (no)
KR (1) KR20010108368A (no)
CN (1) CN1160065C (no)
AR (1) AR029343A1 (no)
AU (1) AU774117B2 (no)
BR (1) BR0009225A (no)
CA (1) CA2359568A1 (no)
IL (1) IL145334A0 (no)
MX (1) MXPA01009448A (no)
MY (1) MY135916A (no)
NO (2) NO330550B1 (no)
NZ (1) NZ513148A (no)
SE (1) SE9901077D0 (no)
WO (1) WO2000056324A1 (no)
ZA (1) ZA200106859B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
EP2260844A1 (en) * 2003-05-27 2010-12-15 Merz Pharma GmbH & Co. KGaA Combination of an NMDA Receptor Antagonist and a Selective Serotonin Reuptake Inhibitor for the Treatment of Depression and other Mood Disorders
AR046314A1 (es) 2003-11-05 2005-11-30 Merz Pharma Gmbh & Co Kgaa Composiciones que comprenden ciclohexilaminas y aminoadamantanos
US8492106B2 (en) * 2004-05-24 2013-07-23 Universitat Zu Koln Identification methods for ergothioneine transporter modulators and therapeutic uses thereof
CN1968684A (zh) * 2004-06-17 2007-05-23 森林实验室公司 美金刚的调释制剂
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
CA2568445C (en) 2004-06-17 2011-05-24 Merz Pharma Gmbh & Co. Kgaa Immediate release formulations of memantine oral dosage forms
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
WO2006058236A2 (en) 2004-11-24 2006-06-01 Neuromolecular Pharmaceuticals, Inc. Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
EP2243475B1 (en) 2005-04-06 2016-01-13 Adamas Pharmaceuticals, Inc. Combination of memantine and donepezil for treatment of CNS disorders
EA013474B1 (ru) * 2005-06-16 2010-04-30 Форест Лэборэтериз, Инк. Композиция в виде гранул с модифицированным и немедленным высвобождением мемантина
WO2008005534A2 (en) * 2006-07-06 2008-01-10 Forest Laboratories, Inc. Orally dissolving formulations of memantine
WO2009151498A2 (en) * 2008-03-28 2009-12-17 Forest Laboratories Holdings Limited Memantine formulations
EP2138173A1 (en) 2008-06-26 2009-12-30 Merz Pharma GmbH & Co.KGaA Pharmaceutical compositions comprising aminoadamantane derivatives
SA109310013B1 (ar) * 2008-12-24 2013-07-28 Astrazeneca Ab مركبات إيثان أمين وطرق لتحضيرها
EP3132793A1 (en) 2009-12-02 2017-02-22 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
WO2013088135A1 (en) * 2011-12-14 2013-06-20 Astrazeneca Ab Gabr-a2 diagnostic
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
HUE045001T2 (hu) 2013-11-05 2019-12-30 Astrazeneca Ab NMDA antagonista prodrugok

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL84305A (en) * 1987-02-06 1992-01-15 Fisons Corp 2-aminoacetamide derivatives
US5206248A (en) * 1992-03-27 1993-04-27 Smith Richard A Method for reducing emotional lability
CZ288519B6 (cs) * 1992-04-03 2001-07-11 Astra Ab (S)-alfa-Fenyl-2-pyridinethanamin, způsob jeho přípravy, farmaceutická kompozice tento enantiomer obsahující, tento enantiomer pro použití jako léčivo a použití tohoto enantiomeru pro výrobu léčiva
ATE229004T1 (de) 1997-03-31 2002-12-15 Korea Res Inst Chem Tech Chinolinische sulfid-derivate als nmda rezeptor- antagonisten und verfahren zu ihrer herstellung

Also Published As

Publication number Publication date
CN1160065C (zh) 2004-08-04
NO20014345L (no) 2001-09-06
ZA200106859B (en) 2002-11-20
MY135916A (en) 2008-07-31
JP4705717B2 (ja) 2011-06-22
AR029343A1 (es) 2003-06-25
JP2002539256A (ja) 2002-11-19
CN1344157A (zh) 2002-04-10
KR20010108368A (ko) 2001-12-07
WO2000056324A1 (en) 2000-09-28
US6479553B1 (en) 2002-11-12
NZ513148A (en) 2003-10-31
CA2359568A1 (en) 2000-09-28
BR0009225A (pt) 2001-12-26
SE9901077D0 (sv) 1999-03-23
EP1162967A1 (en) 2001-12-19
AU774117B2 (en) 2004-06-17
AU4156100A (en) 2000-10-09
NO330550B1 (no) 2011-05-16
NO20014345D0 (no) 2001-09-06
MXPA01009448A (es) 2002-08-06
IL145334A0 (en) 2002-06-30

Similar Documents

Publication Publication Date Title
NO20101069L (no) Anvendelse av visse NMDA-affinitetsantagonister som antidepressiva
NO306237B1 (no) Anvendelse av xantinderivater som antidepressive midler
TW330202B (en) Substituted heterocyclic carboxamide esters, their preparation and their use as pharmaceuticals
HUP0102453A2 (hu) Adenozinszármazékok, alkalmazásuk és e vegyületeket tartalmazó gyógyászati készítmények
MXPA04006322A (es) Derivados de 6-fluorobiciclo[3.1.0]hexano.
DK0590919T3 (da) Terapeutiske midler mod Parkinsons sygdom
UA42684C2 (uk) Похідні бензимідазолону та їх фізіологічно прийнятні кислотно-адитивні солі
HRP20090162T1 (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists
FR2805810B1 (fr) Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation
HRP20070529T3 (en) Imidazole derivatives as glutmate receptor antagonists
HRP20040429B1 (en) Sulphonamide derivatives, the preparation thereof and the application of same as medicaments
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
DK0759919T3 (da) Azolidindioner som antihyperglykæmiske midler
NO20015172L (no) 1-metyl-erytromycin-derivater
MY116280A (en) A combination of a 5-ht reuptake inhibitor and a h5-ht 1b antagonist or partial agonist
DE69231445D1 (de) Triazole enthaltende antifungizide mittel
DK132188A (da) Anvendelse af tetrahydrobenz(c,d)indol-6-carboxamider som anxiolytika
ES2191341T3 (es) Derivados de la 2-fenoxianilina.
ATE374750T1 (de) Serotoninwiederaufnahme-inhibitoren
CO5540322A2 (es) Nuevos derivados heterociclicos que comprenden un anillo de tetrahidroisoquinolina y uso farmaceutico de los mismos
NO20012965L (no) Sulfonyloksazolaminer som terapeutisk aktive forbindelser
NO20022123L (no) Osoksazolderivater for anvendelse som inhibitorer for fosfodiesterase VII
DK1204658T3 (da) Benzofurylpiperazin-serotoninagonister
ATE332695T1 (de) Pyrimidin-derivate als selektive inhibitoren von cox-2
NO961797L (no) Anvendelse av benzopyranderivater for fremstilling av farmasöytiske sammensetninger beregnet for behandling av patologier forbundet med den Na+-uavhengige C1-HCO3-utbytter